Pharmaceutical lobbyists are focusing on a new target - the US agency FDA. According to their statements to STAT, the chances of drug approval will increase if the FDA's decision can be considered a victory for the Donald Trump administration. Lobbyists believe such a framework will help speed up approval processes. This approach represents a surprising change in their strategy. The goal is to influence regulatory decisions in favor of the pharmaceutical industry. Lobbyists emphasized that the connection to the administration's political success could change the results.